RXDX
Ensign Peak Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-177,457
| Closed | -$19M | – | 1791 |
|
|
2023
Q1 | $19M | Buy |
177,457
+8,250
| +5% | +$885K | 0.04% | 289 |
|
|
2022
Q4 | $18.6M | Buy |
169,207
+101,750
| +151% | +$11.2M | 0.04% | 306 |
|
|
2022
Q3 | $3.98M | Buy |
67,457
+65,897
| +4,224% | +$3.89M | 0.01% | 582 |
|
|
2022
Q2 | $44K | Hold |
1,560
| – | – | ﹤0.01% | 2078 |
|
|
2022
Q1 | $59K | Buy |
+1,560
| New | +$59K | ﹤0.01% | 2108 |
|